SUBSCRIBE
SUBSCRIBE
News   Drug Development

Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease

February 1, 2010 | 
1 min read
Bookmark and Share

BASEL, Switzerland--(BUSINESS WIRE)--Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.
Clinical research Phase 2 Europe
MORE ON THIS TOPIC
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Obesity
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
October 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Business
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
October 14, 2026
 · 
1 min read
 · 
Jef Akst
Flags of US, EU and China painted on cracked wall with people shadow
China
European biotech leaders split on US-China fight for deal dominance, survey finds
October 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Target center and arrow with business target concept, 3d rendering. 3D illustration.
mRNA
BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
October 13, 2026
 · 
3 min read
 · 
Heather McKenzie